THT

Bring the Cinematic Thrill Home with JBL's Most Advanced Soundbars Yet

Retrieved on: 
Monday, May 15, 2023
Central Electricity Authority Regulations, Business development, Music, Harvey Norman, ALL, Harman International, Dolby, Sound, Alexa, TWS, AirPlay, JBL, Road show, Wi-Fi, Apple Inc. v. Samsung Electronics Co., Harman, Siri, EQ, Internet, Private company limited by shares, Radio, DTS, AES, HARMAN, Qualcomm code-excited linear prediction, Family, THT, IOI City Mall, Cassette tape, Video game, Mobile phone, Chromecast

At the Roadshow, an experiential soundbar room is specially designed for enthusiasts to feel and experience the JBL Bar 1300.

Key Points: 
  • At the Roadshow, an experiential soundbar room is specially designed for enthusiasts to feel and experience the JBL Bar 1300.
  • There will also be other fun activities for the family, including Human Claw, Dance Challenge, Product Personalisation, and Gatchapon etc.
  • JBL's professional line of speakers are used in more than half of the world's movie theatres, sports stadiums, and music venues.
  • (to include, AI Sound, Flash Gadgets, STY Electric)
    - Find out more about the JBL Bar Series and other products at https://www.jbl.com.my.

Windtree Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Key Business Updates

Retrieved on: 
Monday, April 3, 2023
Exercise, SBP, AHF, Cardiogenic shock, Heart failure, Efficacy, WINT, Research, Experiment, American Society for Pharmacology and Experimental Therapeutics, Biomarker, Arrhythmia, Doctor of Philosophy, Istaroxime, Science, CCU, THT, Heart, Journal, Publication, Patent, MD, Patient, Annual report, Risk, Average cost, Toxicology, Security (finance), ICU, Therapy, Metabolite, Safety, Seismology, Conference, FESC, Pharmaceutical industry, Medical device, Cryptocurrency, Life insurance, Windtree Therapeutics, Pharmacology

WARRINGTON, Pa., April 03, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today reported financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided key business updates.

Key Points: 
  • WARRINGTON, Pa., April 03, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today reported financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided key business updates.
  • Research and development expenses were $1.2 million for the fourth quarter of 2022, compared to $4.5 million for the fourth quarter of 2021.
  • General and administrative expenses for the fourth quarter of 2022 were $2.2 million, compared to $3.0 million for the fourth quarter of 2021.
  • For the fourth quarter ended December 31, 2022, the Company reported an operating loss of $10.8 million, compared to an operating loss of $14.7 million in the fourth quarter of 2021.

Two-Year Study Data for EVBA Procedure with Unique MobiusHD Device Presented at Technology and Heart Failure Therapeutics Meeting

Retrieved on: 
Wednesday, March 22, 2023
Health, Clinical Trials, Cardiology, Medical Devices, Exercise, Learning, NYHA, Heart failure, Carotid sinus, LVEF, Heart, Quality of life, Vanderbilt University Medical Center, City centre, VDI, KCCQ, Heart Failure Society of America, MD, N-terminal prohormone of brain natriuretic peptide, Patient, Autonomic nervous system, THT, Medical device, Medical imaging

Vascular Dynamics, Inc. (VDI) , a privately held medical device company focused on developing game-changing endovascular device-based solutions for patients suffering from heart failure, announced that two-year results from a study assessing its MobiusHD device to treat patients with chronic heart failure were presented today at the Technology and Heart Failure Therapeutics ( THT ) 2023 meeting in Boston.

Key Points: 
  • Vascular Dynamics, Inc. (VDI) , a privately held medical device company focused on developing game-changing endovascular device-based solutions for patients suffering from heart failure, announced that two-year results from a study assessing its MobiusHD device to treat patients with chronic heart failure were presented today at the Technology and Heart Failure Therapeutics ( THT ) 2023 meeting in Boston.
  • The data , presented by JoAnn Lindenfeld, MD, a heart failure specialist at Vanderbilt University Medical Center and Past President of the Heart Failure Society of America, focused on the efficacy of the MobiusHD device implantation in progressive heart failure patients who were previously highly symptomatic despite guideline-directed medical therapy.
  • These results provide evidence suggesting a clinically meaningful and durable benefit of endovascular baroreflex amplification (EVBA) in specific heart failure patients.
  • In this way, the MobiusHD offers a potential device-based solution for symptomatic heart failure patients who are not responding to drug treatment.

Ancora Heart’s AccuCinch System Demonstrates Significant Improvement in Quality of Life, Cardiac Structure and Function in Heart Failure Patients

Retrieved on: 
Wednesday, March 22, 2023
Science, Cardiology, Biotechnology, Research, Pharmaceutical, General Health, Health, Medical Devices, Heart, CRF, NYHA, Freedom, Heart failure, Classification, LVEF, EF, Quality of life, Multimedia, Journal of Cardiac Failure, KCCQ, New York Heart Association Functional Classification, Journal, MD, Manuscript, Maes, Therapy, THT, Pharmaceutical industry, Medical device, HF, Patient

Ancora Heart, Inc ., a company developing a completely transcatheter device-based therapy to address heart failure (HF), today announced that patients treated with the investigational AccuCinch® Ventricular Restoration System demonstrated improvement in HF patient outcomes and beneficial changes in the structure of the heart.

Key Points: 
  • Ancora Heart, Inc ., a company developing a completely transcatheter device-based therapy to address heart failure (HF), today announced that patients treated with the investigational AccuCinch® Ventricular Restoration System demonstrated improvement in HF patient outcomes and beneficial changes in the structure of the heart.
  • The 12-month data were presented as part of a late-breaking clinical science session at the Technology and Heart Failure Therapeutics conference (THT 2023) and simultaneously published in the Journal of Cardiac Failure .
  • “This analysis shows patients treated with the AccuCinch System experienced meaningful improvement in efficacy measures important to both clinicians and patients,” said Dr. Hamid.
  • “We witnessed significant and progressive reverse remodeling of the left ventricle, as well as significant and sustained improvement in quality of life and functional capacity measures.

Aortix Pump Therapy Leads to Rapid Decongestion and Improved Kidney Function in Hospitalized Patients with Heart Failure and Worsening Renal Function

Retrieved on: 
Tuesday, March 21, 2023
Heart, Congestion, Acute decompensated heart failure, Heart failure, MI, CRS, Perfusion, ADHF, FACC, Patient, Swelling, Cardiorenal syndrome, Blood, Abdomen, Mortality, THT, Military Hospital 4/637, Fatigue, Pharmaceutical industry, Medical device, MD

These patients, who were unresponsive to available medical therapy, demonstrated significant improvements in kidney function, cardiac function, and patient-reported assessment of shortness of breath at 30 days after treatment with the Aortix pump.

Key Points: 
  • These patients, who were unresponsive to available medical therapy, demonstrated significant improvements in kidney function, cardiac function, and patient-reported assessment of shortness of breath at 30 days after treatment with the Aortix pump.
  • The results from the CRS pilot study were presented today during the late-breaking clinical science session at the Technology and Heart Failure Therapeutics (THT) conference in Boston.
  • The consistent results indicate the potential of Aortix therapy to be a major therapeutic advancement for CRS patients.
  • The innovative design uses intra-aortic placement and harnesses fluid entrainment to pump blood without the need of a valve and provides physiologically natural delivery of therapy.

Totality of Evidence from BeAT-HF Study Shows CVRx’s Barostim Provides Long-term Benefits for Patients with Heart Failure

Retrieved on: 
Tuesday, March 21, 2023
BAT, ER, Heart failure, Hospital, Confidence, HF, Medical school, Mortality, Rate, Quality, Medical University of South Carolina, Patient, Nursing, Cardiology, Quality of life, Disease, Control, MUSC, LVAD, FDA, Therapy, THT, Pharmaceutical industry, Medical device, Jet fuel

These results are being presented by Dr. Michael Zile, Professor of Cardiology at the Medical University of South Carolina (MUSC).

Key Points: 
  • These results are being presented by Dr. Michael Zile, Professor of Cardiology at the Medical University of South Carolina (MUSC).
  • “We are happy to see the significant long-term data that favored Barostim,” added Nadim Yared, President and CEO of CVRx.
  • “Interest and adoption of the therapy continue to expand based on the previously-approved claims, and now we look forward to submitting this new data to the FDA to pursue expanded labeling for Barostim.
  • CVRx anticipates that regulatory submission to the FDA for expanded labeling will be made in the coming months.

CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call

Retrieved on: 
Thursday, March 16, 2023
MUSC, Telephone, Patient, Medical school, Medical University of South Carolina, Cardiology, Spiceworks News & Insights, THT, Pharmaceutical industry

These results will be presented by Dr. Michael Zile, Professor of Cardiology at the Medical University of South Carolina (MUSC).

Key Points: 
  • These results will be presented by Dr. Michael Zile, Professor of Cardiology at the Medical University of South Carolina (MUSC).
  • Additionally, CVRx will sponsor a symposium, “Baroreflex Activation Therapy in HFrEF: New Insights from the BeAT-HF Study”, at the THT 2023 conference starting at 12:30 pm ET.
  • In conjunction, the Company will host an investor conference call at 4:30 pm Eastern Time the same day to discuss the results.
  • A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com .

Ancora Heart Announces Late-Breaking Clinical Science Presentation Among Key Activities at Technology and Heart Failure Therapeutics Conference

Retrieved on: 
Tuesday, March 14, 2023
Surgery, Hospitals, Clinical Trials, Health Technology, Cardiology, Biotechnology, Health, Pharmaceutical, General Health, HF, Heart failure, Dilation, THT, CRF, Patient, Therapy, Heart, Pharmaceutical industry, Nightclub

Ancora Heart, Inc., a company developing a novel device-based therapy to address heart failure (HF), today announced that a late-breaking clinical science presentation featuring the latest data from studies of the investigational AccuCinch® Ventricular Restoration System will take place at the upcoming Technology and Heart Failure Therapeutics conference (THT 2023).

Key Points: 
  • Ancora Heart, Inc., a company developing a novel device-based therapy to address heart failure (HF), today announced that a late-breaking clinical science presentation featuring the latest data from studies of the investigational AccuCinch® Ventricular Restoration System will take place at the upcoming Technology and Heart Failure Therapeutics conference (THT 2023).
  • This event is produced by the Cardiovascular Research Foundation (CRF) and will be held March 20 - 22 at the Westin Boston Seaport in Boston, Mass.
  • The late-breaking clinical science from Ancora Heart will be presented by Dr. Nadira Hamid, interventional echocardiographer, cardiologist at Allina Health Minneapolis Heart Institute and assistant director of the echocardiographic core lab CRF.
  • The data will include complete 12-month clinical outcomes from an analysis of 51 symptomatic heart failure patients with reduced ejection fraction (HFrEF) who were treated with the AccuCinch System.

Windtree Announces Istaroxime Scientific Abstract Has Been Accepted at the 2023 Technology and Heart Failure Therapeutics Conference

Retrieved on: 
Monday, February 27, 2023
Blood pressure, Windtree Therapeutics, Therapy, SCAI, Patient, Efficacy, Seismology, Heart failure, Cardiac output, SBP, Conference, THT, SVP, Cardiogenic shock, Arrhythmia, Pharmaceutical industry

The Company announced that its abstract entitled “Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients with Pre Cardiogenic Shock” has been accepted for presentation at the Technology and Heart Failure Therapeutics Conference (THT) being held on March 20-22, 2023 in Boston, MA.

Key Points: 
  • The Company announced that its abstract entitled “Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients with Pre Cardiogenic Shock” has been accepted for presentation at the Technology and Heart Failure Therapeutics Conference (THT) being held on March 20-22, 2023 in Boston, MA.
  • “Windtree is pleased to share this analysis of the istaroxime SEISMiC data at the THT Conference,” said Dr. Steve Simonson, Chief Medical Officer and SVP of Windtree Therapeutics.
  • “The positive Phase 2 SEISMiC study demonstrated the potential for istaroxime to simultaneously increase cardiac output and blood pressure.
  • A drug with this unique profile would be a valuable therapeutic tool for the treatment of cardiogenic shock due to heart failure.

CVRx Reports Preliminary Results of the BeAT-HF Post-Market Randomized Clinical Trial

Retrieved on: 
Tuesday, February 21, 2023
Medical University of South Carolina, THT, LVAD, Heart, Safety, Patient, Telephone, News, Webcast, Guideline, Disease, Heart failure, Mortality, Survival, FDA, Education, Professors in the United States, Conference, Quality of life, Medical school, Data collection, Pharmaceutical industry

MINNEAPOLIS, Feb. 21, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, announced today the preliminary topline results of the BeAT-HF, Baroreflex Activation Therapy for Heart Failure, post-market randomized clinical trial.

Key Points: 
  • MINNEAPOLIS, Feb. 21, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, announced today the preliminary topline results of the BeAT-HF, Baroreflex Activation Therapy for Heart Failure, post-market randomized clinical trial.
  • The BeAT-HF post-market phase of the multi-center, prospective, randomized, controlled trial assessed 323 patients suffering from heart failure with reduced ejection fraction.
  • The patients were randomized to two groups, treatment with Barostim and guideline directed medical therapy versus guideline directed medical therapy alone.
  • The trial accrued 332 primary events and had a median follow-up of 3.7 years, corresponding to 1,037 patient-years.